Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Ingo Flamme

Peter Kolkhof

Jens-Kerim Ergüden

Kai Thede

Mario Jeske

Hanno Wild

Friederike Stoll

Hartmut Beck

Felix Oehme

Joachim Schuhmacher

Metin Akbaba

Andreas Knorr

Jörg Keldenich

Alexander Kuhl

Karl-Heinz Schlemmer

Rudolf Schohe-Loop

Hans-Georg Lerchen

Rolf Grosser

Nils Griebenow

Lars Bärfacker

Johannes Köbberling

Sven Wittrock

Santiago Figueroa Perez

Frank Wunder

Dieter Lang

Gorden Redlich

Maria Köllnberger

Iain Pritchard

Julie Marley

Carsten Schmeck

Heike Heckroth

Elisabeth Pook

Chantal Fürstner

Gunter Karig

Klaus Münter

Ulf Brüggemeier

Heike Gielen-Haertwig

Ernst Weber

Dorian Schönfeld

Karoline Dröbner

Joachim Hütter

Katharina Filarsky

Philipp Ellinger

Fionnuala Mary Mcaleese Eser

Kenneth Young

Yalda Sedaghat

Antje Schmidt

Winfried Wunderlich

Adrian Tersteegen

Heinrich Meier

Axel Kretschmer

Martina Delbeck

Joerg Keldenich

Daniel Meibom

Dagmar Karthaus

Simon Holton

Dmitry Zubov

Thomas Neubauer

Ursula Krenz

Donald Bierer

Dirk Schneider

Carsten Terjung

Eckhard Bender

Adam Nitsche

Jan Dreher

Lars Baumann

Yibo Qiu

Jiancheng Xiong

Thorsten Poethko

Marie Glatz

Cathleen Juhl

Hubert Truebel

Johannes Kobberling

Maria Koellnberger

July Marley

Chantal FÜRSTNER

Uif BRÜGGEMEIER

The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Semaphorin 3A (Sema3A). An antibody conjugate and a pharmaceutical composition each comprising the isolated antibody or antigen-binding fragment thereof that binds to human Sema3A are also provided.

Anti-semaphorin 3A antibodies

The present disclosure relates to an isolated antibody or antigen-binding fragment thereof that binds to human Sema3A. The isolated antibody or antigen-binding fragment according to the present disclosure i) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; ii) cross-reacts with mouse, cynomolgus, rat, pig and/or dog Sema3A, particularly wherein said isolated antibody or antigen-binding fragment thereof binds to mouse, cynomolgus, rat, pig and/or dog Sema3A with a dissociation constant (KD)≤50 nM, ≤20 nM, ≤10 nM, ≤1 nM, or ≤0.1 nM; iii) binds to human Sema3A of the sequence of SEQ ID NO: 600 with a binding activity as measured by surface plasmon resonance (SPR) of ≥60%, ≥70%, ≥80%, or ≥90%; iv) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro mesangial cell migration assay with an EC50 of ≤10 nM, ≤5 nM, ≤2.5 nM, or ≤1 nM; v) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro growth cone collapse assay with an EC50 of ≤50 nM, ≤25 nM, ≤10 nM, or ≤5 nM; vi) inhibits the activity of human Sema3A of the sequence of SEQ ID NO: 600 in an in vitro HUVEC repulsion assay with an EC50 of ≤1 nM, or ≤0.3 nM, ≤0.1 nM, ≤0.07 nM, ≤0.06 nM and/or vii) exhibits an increased potency against cellular Sema3A, of the sequence of SEQ ID NO: 600, induced HUVEC repulsion.

Anti-sema3a antibodies and uses thereof

The present invention relates to novel Mannose-binding lectin (MBL)-associated serine protease (MASP) inhibitory compounds, as well as analogues and derivatives thereof, to processes for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of renal and cardiovascular disorders and of ischemia reperfusion injuries.

MASP inhibitory compounds and uses thereof

The invention relates to novel polyethylene glycol (PEG) based prodrug of Adrenomedullin, to processes for preparation thereof, to the use thereof for treatment and/or prevention of diseases, and to the use thereof for producing medicaments for treatment and/or prevention of diseases, especially of cardiovascular, edematous and/or inflammatory disorders.

Polyethylene glycol based prodrug of adrenomedullin and use thereof

The invention relates to novel tyrosine based linkers that allow the releasable connection of peptides or proteins with other molecular entities, e.g. polyethylene glycol, to processes for their preparation and their use for preparing medicaments for the treatment and/or prophylaxis of diseases.

Tyrosine based linkers for the releasable connection of peptides

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dihydropyrazolones for treating cardiovascular and hematological diseases

The present application relates to novel dipyridyl-dihydropyrazolones, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

4-(pyridin-3-yl)-2(pyridin-2yl)-1,2-dihydro-3H-pyrazol-3-one derivatives as specific HIF-pyrolyl-4-hydroxylase inhibitors for treating cardiovascular and haematological diseases

The present application relates to new, substituted benzyl-1,2,4-triazolones and phenylsulfonyl-1,2,4-triazolones, to processes for preparing them, to their use alone or in combinations for the treatment and/or prevention of diseases and also to their use for the production of medicaments for the treatment and/or prevention of diseases, more particularly for the treatment and/or prevention of cardiovascular disorders.

Substituted benzyl and phenylsulfonyl triazolones, and use thereof

The present application relates to novel substituted dipyridyldihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and hematological diseases and kidney diseases, and for promoting wound healing.

Substituted dipyridyl-dihydropyrazolones and use thereof

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Substituted dihydropyrazolones and their use

Substituted dihydropyrazolones and use thereof as HIF-prolyl-4-hydroxylase inhibitors

Growing community of inventors

Reichshof, Germany

Ingo Flamme